Advertisement

Topics

Brainstorm Cell Therapeutics Company Profile

04:03 EST 22nd November 2017 | BioPortfolio

BrainStorm (OTC BB: BCLI) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult stem cells taken from the patient's own bone marrow to treat diseases such as Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) and Multiple Sclerosis (MS). The adult stem cells are used to create healthy new brain-like cells that replace or support the diseased cells. Patients treated with the Company’s NurOwn™ therapeutic cells are expected to enjoy a rapid recovery and much enhanced quality of life. BrainStorm's therapy has the potential to cure underlying pathology, rather than simply treat symptoms. BrainStorm's management and scientific teams are passionately devoted to the Company's mission: regenerating the mind... in their lifetime.

Location

110 East 59th Street
New York
10022
United States of America

Contact

Phone: (212)-557-9000
Fax: (212)-581-8958
Email: info@brainstorm-cell.com


News Articles [2048 Associated News Articles listed on BioPortfolio]

BrainStorm gets $15.9M funding from CIRM

BrainStorm Cell Therapeutics has received $15.9 million in funding from the California Institute for Regenerative Medicine to -More- 

BrainStorm enrolls first patients in advanced ALS stem cell trial

TEL AVIV (Reuters) - BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hos...

Brainstorm to Host Second-Quarter 2017 Earnings Teleconference and Provide Important Corporate ...

HACKENSACK, N.J.and PETACH TIKVAH, Israel, Aug. 10, 2017/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem Read more...

BrainStorm sign pact with Massachusetts General Hospital & CPMC to participate in phase 3 trial of NurOwn in ALS

BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, has signed definitive agreements with Massachusetts General Hospital and California Pa...

Brainstorm to Announce Third Quarter Financial Results And Provide Corporate Updates on Tuesday, October 17

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Oct. 3, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerativ...

Brainstorm secures $16m grant for phase 3 trial of NurOwn in ALS

The California Institute for Regenerative Medicine (CIRM) has awarded a grant of $16m to Brainstorm Cell Therapeutics to support a phase 3 study of NurOwn for the treatment of amyotrophic lateral scle...

BrainStorm chooses Worldwide as CRO for Phase III ALS trial

US-based biotechnology company BrainStorm Cell Therapeutics has chosen Worldwide Clinical Trials as the clinical research organisation (CRO) for its upcoming Phase III clinical trial of NurOwn for tre...

BrainStorm Cell Therapeutics' (BCLI) CEO Chaim Lebovits on Q3 2017 Results - Earnings Call Transcript

PubMed Articles [3328 Associated PubMed Articles listed on BioPortfolio]

Mechanisms of the Amplifying Pathway of Insulin Secretion in the β Cell.

Pancreatic islet β cells secrete insulin in response to nutrient secretagogues, like glucose, dependent on calcium influx and nutrient metabolism. One of the most intriguing qualities of β cells is ...

How do i participate in T-cell immunotherapy?

T cells play a key role in the adaptive immune response, and the ability to manipulate T cells for therapeutic uses has advanced in the past decade. Infusion of expanded or engineered T cells can pote...

T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics.

Harnessing the power of the human immune system to treat cancer is the essence of immunotherapy. Monoclonal antibodies engage the innate immune system to destroy targeted cells. For the last 30years, ...

Tocilizumab (Actemra) for giant cell arteritis.

Delivery of therapeutics to posterior eye segment: cell-encapsulating systems.

Clinical Trials [5462 Associated Clinical Trials listed on BioPortfolio]

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease

This study evaluates the safety and clinical benefits of a therapeutics approach of conditioning regimen Cyclophosphamide (Cy) + Thymoglobulin r (ATG) + Granulocyte Colony-Stimulating Fact...

Companies [2032 Associated Companies listed on BioPortfolio]

BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a promising company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of ne...

Brainstorm Cell Therapeutics

BrainStorm (OTC BB: BCLI) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult st...

BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of ne...

Magenta Therapeutics

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based dise...

Opsis Therapeutics

Opsis Therapeutics is a company focused on discovering and developing new medicines to restore vision to patients suffering from retinal diseases. By combining recent innovations ...

More Information about "Brainstorm Cell Therapeutics" on BioPortfolio

We have published hundreds of Brainstorm Cell Therapeutics news stories on BioPortfolio along with dozens of Brainstorm Cell Therapeutics Clinical Trials and PubMed Articles about Brainstorm Cell Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Brainstorm Cell Therapeutics Companies in our database. You can also find out about relevant Brainstorm Cell Therapeutics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...


Corporate Database Quicklinks



Searches Linking to this Company Record